

Choose A Program Program: FECA Org. Name: ANGELA ATL & FLA TEST M.D. Provider ID: 001015621

- FECA
- Main
- Medical Authorization
- Entry
- Claim Entry
- LMN Form Submission
- Inquiries
- Eligibility & Accepted Conditions
- Bill Status
- Medical Authorization
- Payment Status
- LMN Documentation
- Administration
- Change Password
- Provider Information
- User Administration
- Enrollment
- Provider Enrollment
- Status Inquiry
- Web Registration

LMN Form Submission

To view documents related to your submitted LMN requests, please click the 'LMN Documentation' hyperlink in the left navigation menu.  
 Instructions - CA 27 LMN Opioid Medications Form OMB No. 1240-0055  
 Instructions - CA 26 LMN Compounded Drugs Form Expires: 10/31/2019  
 Jan 2017

Please specify which type of LMN request you would like to Enter

Opioid (CA 27 LMN Opioid Medications)

Opioid-Compounded (CA 27 LMN Opioid Medications)

Non Opioid Compounded (CA 26 LMN Compounded Drugs)

Authorization Request form and Certification/Letter of Medical Necessity for Opioid Medications  
 This form is to be completed and signed by the patient's treating physician. Complete all sections of this form. Failure to complete this form in its entirety may result in delayed processing or an adverse determination for insufficient information. The form is valid and effective for up to 90 days following the date of the treating physician's signature/certification.

Part A - Patient Information

1. \*Last Name:  \*First Name:  Middle Initial:

2. \*Patient OWCP #:  3. Street Address:

4. \*Date of Birth:  mm  dd  yyyy 5. City:  6. State:

7. Zip:  8. Phone #:

Part B - Treating Physician Information

9. \*Treating Physician Name:  10. \*Treating Physician NPI #:

11. \*Street Address:  12. \*Provider ID#: 001015621

13. \*DEA #:  14. \*City:  15. \*State:

16. \*Zip:  17. \*Phone #:  18. Secure Fax #:

Part C - Opioid Medication Information - PLEASE NOTE LIMIT OF TWO

19. \*Medication Name(s):  20. \*Primary Diagnosis:

21. \*NDC(s):  22. \*ICD-10 Code:

23. \*Directions for use:  24. \*Date of Last Physical Examination:  mm  dd  yyyy

25. \*Route of Administration (and Code):

26. \*Anticipated Length of Therapy:

27. \*Daily morphine milligram equivalent dose:

Part D - Certification of Medical Necessity

28. \*Have you accessed the requisite state Prescription Drug Monitoring Program, if available, regarding this patient's history of controlled substance prescriptions and will you do so every month thereafter?  
 Yes  No  I do not have access to a [PDMP] in my state

29. \*Will you enter this prescription information into your state's Prescription Drug Monitoring Program if you are required to update it as a dispensing provider?  Yes  No

30. \*Have you completed a urine drug test for the above-named patient and will you do so periodically?  Yes  No

31. \*Is the patient receiving a benzodiazepine from you or any other provider while receiving an opioid prescription?  
 Yes  No  I do not have access to a [PDMP] in my state

32. \*Have you discussed realistic benefits and known risks of opioid therapy with the patient, and have you advised the patient that serious risks include potentially fatal respiratory depression and development of a potentially serious lifelong opioid use disorder?  Yes  No

33. \*Did you evaluate the use of non-opioid alternatives and conclude with reasonable medical certainty that the opioid's expected benefits for both pain and function outweigh the risk to the patient? SUPPLY NARRATIVE IN ITEM 40.  Yes  No

34. \*Have you evaluated the patient for risk of opioid use disorder, potential need for medication-assisted treatment (MAT), and believe the medical benefit of prescribing the opioid outweighs the risk? SUPPLY NARRATIVE IN ITEM 40.  Yes  No

35. \*Have you discussed with the patient the potential risk for opioid overdose or other adverse reaction and the steps the patient can take to reduce their risk, such as not combining their opioid with alcohol or other sedating substances?  Yes  No

36. \*For patients who are at increased risk for overdose (as defined in the CDC guidelines) have you offered a prescription for overdose reversal (for example, naloxone) or counseled the patient to obtain naloxone from their pharmacy, where available without a prescription?  Yes  No

37. \*Has use of the opioid medication(s) improved both pain and function for the patient?  Yes  No

38. \*Is the opioid medication medically necessary for its intended use?  Yes  No

Ingredients

39. If the requested opioid medication is prescribed in a compounded drug, list opioid ingredients in box. 21. Complete the following for all other non-opioid active and inactive ingredients in the compounded drug: IF MORE THAN TEN ACTIVE/INACTIVE INGREDIENTS ARE BEING USED, LIST (INCLUDING NAME, NDC, QUANTITY, STRENGTH, AND MEDICAL NECESSITY FOR EACH) AND EXPLAIN THE NEED FOR MORE THAN TEN IN ITEM NUMBER 40. Only the most cost effective and medically necessary ingredients should be used. Herbal supplements such as resveratrol, lavender oil, and alpha-lipoic acid, cannot be authorized on this form and will cause the form to be returned to the provider. Herbal supplements are authorized only on an exception basis on approval by the OWCP Chief Medical Officer or his/her designee.

\*Drug Name  \*NDC(s)

\*Quantity  \*Strength  \*Medically Necessary?  Yes  No

40. \*Provide a narrative explaining why the opioid medication is medically necessary. You may cite relevant medical literature to support your opinion on the necessity of the medication, particularly if the opioid is part of a compounded drug. You may be asked to provide clinical documentation and other relevant evidence to support use of this medication. The need for this medication is subject to review by claims staff and medical professionals. See instructions in item number 39 if the opioid is part of a compounded drug that has more than ten ingredients.

I certify that I am the treating physician for the above-named patient and that the medication requested is medically necessary and cost effective for the patient. I further certify, under penalty of law, that the information provided on this form is true and correct to the best of my knowledge, and that documentation supporting this information is available for review if requested. I understand that any person who knowingly makes any false statement or misrepresentation to obtain prescription drugs from OWCP is subject to administrative penalties including provider exclusion, civil penalties including those under the False Claims Act and/or criminal prosecution. The submission of this form signifies my certification of the above and the on-line signature on my provider enrollment form is hereby incorporated by reference.

41. \*Signature/CERTIFICATION of Patient's Treating Physician  \* Yes  No  42. Date  mm  dd  yyyy  
 05 26 2017

Public Burden Statement  
 Public reporting burden for this collection of information is estimated to average 30 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. If you have any comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, send them to the Office of Workers' Compensation Programs, U.S. Department of Labor, Room 33524, 200 Constitution Avenue, N.W., Washington, D.C. 20210. Do not submit the completed claim form to this address. Persons are not required to respond to this information collection unless it displays a currently valid OMB number.

\*denotes required fields